Alyssa Shon

Hypervirulent K. Pneumoniae Secretes More and More Active Iron-Acquisition Molecules than “Classical” K. Pneumoniae Thereby Enhancing its Virulence

Thomas A. Russo, Alyssa Shon, Janet M. Beanan et al. · PLoS ONE · 2011 · 135 citations · Full text

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

Susan Swindells, Thomas A. Lutz, Lelanie Van Zyl et al. · AIDS · 2021 · 92 citations · Full text

Extension Results, Pharmacotherapy, Antiviral Drug +18

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.

Susan Swindells, Thomas A. Lutz, Lelanie Van Zyl et al. · AIDS · 2022 · 49 citations · Full text

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Chloe Orkin, Jean‐Michel Molina, Pedro Cahn et al. · The Lancet HIV · 2023 · 25 citations · Full text

First-line Therapy, Open-label Extensions, Antiviral Drug Development +7

Biofilm formed by a hypervirulent (hypermucoviscous) variant of Klebsiella pneumoniae does not enhance serum resistance or survival in an in vivo abscess model

Qingli Kong, Janet M. Beanan, Ruth Olson et al. · Virulence · 2012 · 21 citations · Full text

Microbial Pathogens, Klebsiella Pneumoniae, Bacteriology +22